Latest News

The final recommendations were directly shaped by data from 36 published articles.

Phase 2 data show an outpatient fixed-duration combo yields 79% complete responses and 18.6-month PFS in relapsed mantle cell lymphoma.

The approval of daraxonrasib in pancreatic cancer is supported by results from the phase 3 RASolute 302 trial.

FDA issues third CRL for lower-dose dasatinib Dasynoc over manufacturing, not data, as Xspray races to resubmit amid PPI absorption benefits.

An exploratory analysis from the SECOMBIT trial showed differences in outcomes based on thymidine kinase activity in BRAF-mutated melanoma treated with immunotherapy and targeted therapy.

The benefit of daraxonrasib in PDAC may be overstated in RASolute 302 due to informative censoring.

The MODeFIRe-1 trial of MRT-2359 plus apalutamide will focus on AR mutations in metastatic castration-resistant prostate cancer.

In an interview, Surbhi Sidana, MD, explores the significance of iberdomide's FDA approval and how this agent fits into the growing array of novel multiple myeloma therapies.

The FDA approved 2 zanidatamab-based regimens for first-line HER2-positive gastroesophageal adenocarcinoma, based on phase 3 HERIZON-GEA-01 data.

In transplant-ineligible or transplant-deferred multiple myeloma, the quadruplet regimen demonstrated sustained benefit in minimal residual disease negativity at nearly 5 years.

Adding radium-223 to cabozantinib did not improve skeletal event-free survival in the phase 2 RADICAL trial of renal cell carcinoma with bone metastases.

Cancer trials enroll more women but rarely compare outcomes by sex, leaving safety gaps and urging equity-focused study design.

Second-line platinum plus pemetrexed produced an 11.5-month median OS and 72% disease control after first-line nivolumab/ipilimumab in pleural mesothelioma.

Experts weigh continuous vs time‑limited CLL therapy, compare acalabrutinib and zanubrutinib, and debate when pirtobrutinib fits first line.

CMS eyes new 340B drug payment rule: cuts beneficiary costs, shifts billions to outpatient services, and boosts reimbursements for many rural hospitals.

A survey of multiple transplant centers found a lack of consistent use of comprehensive screening for chronic GVHD; lead author Laila Alkhouli explained the significance of these findings.

Two peer-reviewed publications cite ProSense cryoablation FDA authorization and ASBrS guidelines, and extend its use to axillary lymph node disease.

During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed how aggressively to bridge a CAR T-eligible patient with high-risk relapsed myeloma.

The FDA has granted fast track designation to safusidenib, an oral IDH1 inhibitor, based on durable phase 2 J201 study responses in IDH1-mutant glioma.

The FDA has granted breakthrough therapy and fast track designations to 68Ga-NYM096, a PET imaging agent for clear cell renal cell carcinoma.

The FDA has granted fast track designation to PLN-101095 plus pembrolizumab for ICI-refractory advanced or metastatic solid tumors.

During a Community Case Forum event, Manojkumar Bupathi, MD, MS, and participants discussed how drug interactions, cost, and day-to-day tolerability are what separate one ARPI regimen from another in hormone-sensitive prostate cancer.

The FDA has granted fast track designation to BH-30643, an oral OMNI-EGFR inhibitor, for advanced EGFR C797S-positive non–small cell lung cancer after a third-generation TKI.

Agentic AI streamlines oncology decisions and trial matching, cutting administrative load, flagging care gaps, and widening community access to studies.

The individualized neoantigen therapy intismeran autogene improved recurrence-free survival over pembrolizumab alone in patients with fully resected melanoma.

The FDA has granted fast track designation to ETX-19477, an oral PARG inhibitor, for BRCA-mutated, HR+/HER2– unresectable or metastatic breast cancer.

During a live event, Sudarsan Kollimuttathuillam, MD, and participants discussed how real-world practice for preventing febrile neutropenia in extensive-stage small cell lung cancer often runs ahead of formal risk stratification.

The designation is for sapanisertib/serabelisib (Piktor) plus chemo in patients who have progressed after chemo and an immune checkpoint inhibitor.

Following the FDA approval of vusolimogene oderparepvec plus nivolumab, melanoma specialists are preparing for real-world clinical use while rethinking how to design future intratumoral therapy trials.

AstraZeneca is discontinuing the phase 3 eVOLVE-Lung02 trial after finding volrustomig plus chemotherapy unlikely to meet its primary end points in metastatic NSCLC.

Trastuzumab deruxtecan improved progression-free survival vs chemoimmunotherapy in the phase 3 DESTINY-Lung04 trial in HER2-mutant NSCLC.